Stockwinners Market Radar for January 28, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:13 EST Philip Morris to partner with KT&G on smoke-free products outside South Korea - Philip Morris (PM) announces a global collaboration agreement with the leading tobacco and nicotine company in South Korea, KT&G, to commercialize KT&G's smoke-free products outside of the country. The agreement will run for an initial period of three years. The two companies plan for global collaboration with the intention to actively expand to cover many markets, based on commercial success. The agreement allows PMI to distribute current KT&G smoke-free products, and their evolutions, on an exclusive basis, and does not restrict PMI from distributing its own or third-party products.

19:04 EST Nissan 'welcomes' Renault's appointment of Luca de Meo as CEO - Nissan (NSANY) said it welcomes the Renault (RNLSY) board of directors' appointment of Luca de Meo as CEO. Over the last 20 years, Nissan and its Alliance partner Renault have worked together to forge a unique and successful partnership based on defining common goals and leveraging individual strengths, while respecting each company's identity and autonomy based on a win-win spirit, Nissan said. As a key source of competitive advantage and a driver of long-term sustainable growth, Nissan said it sees the Alliance as essential to its performance recovery. Nissan will continue to work to reinforce collaboration in existing and new areas across the Alliance. "I am very happy with the Renault Board's decision to appoint Luca de Meo as CEO," said Representative Executive Officer, President and CEO Makoto Uchida. "We are all looking forward to working closely with him and our Alliance partners in our efforts to support mutually profitable growth."

18:53 EST SensorTower says Nintendo mobile titles reach $1B in lifetime player spending - According to SensorTower's Store Intelligence data, Nintendo's (NTDOY) mobile games have generated more than $1B in lifetime revenue from global player spending on the App Store (AAPL) and Google Play (GOOG). Nintendo's mobile repertoire, which comprises six games, has also amassed a combined 452M downloads worldwide. The majority of the revenue, specifically $656M or 61%, has come from strategy role-playing game "Fire Emblem Heroes," according to SensorTower. The next two highest-grossing Nintendo titles were "Animal Crossing: Pocket Camp," which has accounted for 12% of all user spending among the company's mobile games, followed by "Dragalia Lost" at 11%. "Mario Kart Tour" and "Super Mario Run" contributed smaller shares of overall revenue at 8% and 7%, respectively, with "Dr. Mario World" following with less than 1%. Nintendo is most successful in its home market of Japan, where the $581M it's earned totals 54% of its overall mobile game revenue; the U.S. has come in second with $316M, or 29%. This distribution is reflected across all its mobile games with the exception of "Mario Kart Tour" and "Super Mario Run," whose spending skews more towards the U.S. The overall revenue distribution among Nintendo's mobile games is a stark contrast to the downloads share; "Super Mario Run" holds the crown with 244M downloads, or 54% of the publisher's 452M mobile game downloads, while the 147M installs of "Mario Kart Tour" represented 32%. "Fire Emblem Heroes," Nintendo's highest-grossing title, has only accounted for 4% of the total.

18:47 EST Masimo CEO: Data sharing is important - In an interview on CNBC's Mad Money, Masimo CEO Joe Kiani discussed health data privacy. He said, "Privacy rules are there to protect patients, not harm them. We used to hoard our data, but patients end up getting harmed by that practice." Kiani encouraged the sharing of health data to prevent unnecessary deaths.

18:32 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: Macom (MTSI) up 13.4%... Accuray (ARAY) up 10.1%... Maxim Integrated (MXIM) up 3.3%... Costamare (CMRE) up 2.8%... MKS Instruments (MKSI) up 2.0%... Apple (AAPL) up 1.1%... Stryker (SYK) up 0.9%. ALSO HIGHER: Conatus Pharma (CNAT) up 20.0% after entering merger with Histogen. DOWN AFTER EARNINGS: Xilinx (XLNX) down 8.7%... CH Robinson (CHRW) down 7.2%... eBay (EBAY) down 5.2%... AMD (AMD) down 3.9%... Mercury Systems (MRCY) down 1.9%... Trustmark (TRMK) down 1.8%... Starbucks (SBUX) down 1.0%. ALSO LOWER: Biohaven (BHVN) down 10.7% after equity offering... Cerus (CERS) down 5.8% after equity offering... Establishment Labs (ESTA) down 3.4% after equity offering... Match Group (MTCH) down 1.2% after CEO transition. Movers as of 18:15ET.

17:58 EST Facebook VP of Engineering Jay Parikh leaving the company - Facebook's Vice President of Engineering Jay Parikh is leaving the social media giant after more than a decade. Parikh, who was considered to be vital in creating the data center infrastructure,announced the move on his Facebook page Tuesday afternoon.Parikh said in the post: "I have some bittersweet news to share. It's time for me to step out of Facebook to explore what's next. The past 10 years has undoubtedly redefined my expectations on what it means to scale and grow. When I first joined Facebook back in 2009, our entire engineering team sat in one building all on one floor, and we were buying off-the-shelf servers and renting data center space. We supported a few hundred million people mostly using the facebook.com website. I don't think any of us could have imagined that we would now be supporting a global community of almost 3 billion people using our family of apps mostly on mobile phones." Reference Link

17:50 EST Alaska Air sees FY20 CapEx approximately $750M - Comments taken from investor presentation slides.

17:48 EST Alaska Air sees FY20 capacity up ~3%-4% - Sees FY20 CASM-ex fuel and special items up ~2%. Comments taken from investor presentation slides.

17:40 EST Value Act boosts stake in Trinity Industries to 20.9% from 20.3% - Value Act increased its stake in Trinity Industries to 20.9% from the 20.3% stake it reported on December 10. Value Act's stake increased from 24,889,998 shares in Trinity to 25,613,507 shares reported in today's filing. This stake allows for Activism.

17:36 EST Apple CEO Cook says company has some suppliers in Wuhan area - Says working on potential mitigation plans. Says impact on suppliers outside Wuhan is less clear at this time, but Apple has attempted to account for wider range of outcomes with a wider China revenue guidance. Says many China Apple stores have reduced opening areas. Says taking additional precautions with cleaning Apple stores in China. Says that while sales in Wuhan are small, retail traffic in China's outside areas has been impacted. Comments taken from Q1 earnings conference call Q/A.

17:29 EST Vaccinex Chairman Albert Friedberg purchased almost $5M in company shares - Vaccinex Chairman Albert Friedberg disclosed in a regulatory filing that he had purchased 982,318 shares of company stock on January 23 at an average price of $5.09 per share. The total transaction value of the purchase was $4,999,999.

17:27 EST Starbucks says coronavirus in China to impact Q2, FY20 results

17:26 EST eBay down 5% to $34.39 after Q4 results, FY20 guidance

17:15 EST Lockheed Martin awarded $185.03M Navy contract for SEWIP system production - Lockheed Martin was awarded a $185.03M firm-fixed-price contract for follow-on full rate production of Surface Electronic Warfare Improvement Program AN/SLQ-326, AN/SLQ-32A6 and AN/SLQ-32C6 systems. Surface Electronic Warfare Improvement Program, or SEWIP, is an evolutionary acquisition and incremental development program to upgrade the existing AN/SLQ-32 electronic warfare system. SEWIP provides enhanced shipboard electronic warfare for early detection, analysis, threat warning and protection from anti-ship missiles. AN/SLQ-326, the latest fielded variant of the AN/SLQ-32, incorporates receiver, antenna and combat system interface upgrades developed under the SEWIP Block 2 ACAT II program and adds the high gain high sensitivity adjunct sensor developed under the SEWIP Block 1B3 ACAT II program. Work will be performed in Liverpool, New York and Lansdale, Pennsylvania, and is expected to be completed by April 2022. This contract includes options, which if exercised, would bring the cumulative value of this contract to $812.06M, and would be completed by September 2026 if all options are exercised. FY18 shipbuilding and conversion and FY20 other procurement funding in the amount of $185.03M will be obligated at time of award and will not expire at the end of the current fiscal year. This contract was competitively procured via the Federal Business Opportunities website with two offers received. The Naval Sea Systems Command is the contracting activity.

17:08 EST Apple CEO says Apple TV+ is off to a 'rousing start' - Says Apple Pay revenue and transactions has doubled from last year. Says demand for Air Pods continues to be "phenomenal", particularly for Air Pods Pro. Says Apple Watch has set new record in the quarter. Comments taken from Q1 earnings conference call.

17:06 EST First Commonwealth boosts dividend 10.0% over previous quarter - First Commonwealth Financial Corporation declared a quarterly common stock dividend of $0.11 per share, which is payable on February 21 to shareholders of record as of February 7. This dividend represents a 10.0% increase over the previous quarter and a 3.2% projected annual yield utilizing the January 27 closing market price of $13.82. First Commonwealth's capital ratios for Total, Tier I, Leverage and Common Equity Tier I at December 31, 2019 were 14.3%, 12.0%, 10.2% and 10.9%, respectively. First Commonwealth's current capital levels exceed the fully phased-in Basel III capital requirements issued by U.S. bank regulators.

17:00 EST Iberiabank raises quarterly dividend to 47c from 45c per share - The dividend is payable on April 1, 2020, to shareholders of record as of March 13, 2020.

16:55 EST Superconductor Technologies' plan includes 70% workforce reduction

16:55 EST FS Bancorp raises dividend 5% to 21c - The Board of Directors approved a 1c increase in the quarterly dividend to 21c, or 84c annually. The quarterly dividend will be paid on February 19, to shareholders of record as of February 5, 2020.

16:43 EST Xilinx down 8% after Q4 revenue view misses estimates, 7% workforce reduction - In after-hours trading, shares are down 8.4% to $90.35.

16:40 EST Apple CEO Tim Cook says highest revenue ever driven by strong iPhone demand - "We are thrilled to report Apple's highest quarterly revenue ever, fueled by strong demand for our iPhone 11 and iPhone 11 Pro models, and all-time records for Services and Wearables," said Tim Cook, Apple's CEO. "During the holiday quarter our active installed base of devices grew in each of our geographic segments and has now reached over 1.5B. We see this as a powerful testament to the satisfaction, engagement and loyalty of our customers - and a great driver of our growth across the board."

16:38 EST Correction: Alaska Air reports Q4 traffic up 3.9%, capacity up 3.5% - Load factor increased 0.4 pts to 83.7%

16:36 EST Gladstone completes acquisition of three building industrial portfolio - Gladstone announced that it completed the acquisition of a 320,838 square foot, three building industrial portfolio with locations in Houston, Texas; Charlotte, North Carolina and St. Charles, Missouri.The portfolio, acquired in a sale/leaseback transaction, is 100% leased to Eastern Metal Supply with a 20 year lease term. Eastern Metal Supply uses the three properties for the warehousing and distribution of aluminum extrusions.

16:32 EST BioPharmX, Timber Pharmaceuticals enter merger agreement - BioPharmX and Timber Pharmaceuticals, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, announced that they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of BioPharmX's stockholders and Timber's members, a wholly-owned subsidiary of BioPharmX will be merged with and into Timber, with Timber surviving the merger as a wholly-owned subsidiary of BioPharmX. As a condition to the closing of the Merger, Timber has agreed to secure not less than $20M of financing for the combined company. The Merger is currently expected to be completed in the second calendar quarter of 2020. Upon completion of the Merger, BioPharmX will change its name to Timber Pharmaceuticals, Inc. and the officers and directors of Timber will become the officers and directors of BioPharmX.

16:28 EST Discover CIO sells 15,000 common shares - In a regulatory filing, Discover Financial EVP and chief information officer Glenn P. Schneider disclosed the sale of 15,000 common shares of the company at a price of $74.212 per share on January 27.

16:27 EST eBay raises dividend 14%, expands share repurchase plan by $5B - Board of Directors declared a quarterly dividend of 16c per share, a 14% increase from the prior quarterly dividend, and expands share repurchase authorization by an additional $5B. The dividend is payable on March 20 to stockholders of record as of March 2.

16:25 EST Reinsurance Group reports Q4 net premiums $2.99B vs. $2.81B last year

16:25 EST Rollins raises dividend 14.3% to 12c - Rollins announced that the Board of Directors approved a 14.3% increase in the Company's quarterly cash dividend. The increased regular quarterly cash dividend of 12c per share is payable March 10 to stockholders of record at the close of business on February 10. This marks the 18th consecutive year the Board has increased its dividend a minimum of 12.0% or more.

16:24 EST Xilinx says plans to reduce global workforce by approximately 7% - Xilinx announced cost-saving measures designed to drive structural operating efficiencies across the company. Xilinx expects to reduce its global workforce by approximately 7% through a targeted reduction in force and meaningfully slower hiring to replace attrition. In addition to the targeted reduction in force, Xilinx is taking other measures to reduce operating expenses, including further reducing discretionary spend and targeting additional operating efficiencies across the business. As a result of these measures, Xilinx expects to generate non-GAAP cost and operating expense savings of approximately $17M-$20M in the fourth quarter. Additionally, Xilinx expects to incur a GAAP pre-tax charge of approximately $25M-$30M in the fourth quarter of fiscal 2020 primarily related to severance pay expenses. "As expected, our fiscal third quarter was a challenging quarter and our revenue came in near the midpoint of our guidance. Given the revenue headwinds we experienced during the quarter, we took actions to reduce our operating expenses which delivered earnings greater than our expectations. Fiscal fourth quarter revenue is expected to grow on a sequential basis as a result of strength in our core vertical markets and a moderate resumption of growth in our data center business. However, we are seeing greater than expected weakness in our wired and wireless business due to a slowdown in both 5G and wired infrastructure deployments, in addition to ongoing global trade headwinds. We expect some of these headwinds in our wired and wireless business to be persistent, resulting in revenue growth lower than our prior expectations. We are, therefore, taking several actions to further reduce our operating expenses this quarter. These are difficult actions, but we believe the decisive steps we are taking to reset our operating expenses will allow us to drive our growth strategy and technology roadmap while enabling a more appropriate level of operating profitability. We remain extremely focused on our mission and long-term growth opportunities as the leader in adaptable platforms from the cloud to edge to endpoints," said Victor Peng, president and CEO.

16:23 EST Match Group names Sharmistha Dubey as CEO, Swidler as COO - Match Group announced that Mandy Ginsberg will be leaving the company and stepping down from the board of directors. Ginsberg will be handing the reigns to "her longtime deputy," Shar Dubey, who currently serves as the President of Match Group, the company announced. Dubey will assume her role effective March 1. The company has also named Gary Swidler as Chief Operating Officer, in addition to his role as Chief Financial Officer. The company has also named Faye Iosotaluno as its Chief Strategy Officer and Justine Sacco as Chief Communications Officer. Both executives will continue to report to Swidler. Match Group Chairman Joey Levin said, "Mandy will always be a part of the Match Group family, wherever she is. But, if she will no longer be here, we cannot imagine a better successor than Shar. The Match Group leadership team has a deep bench of talent, and Shar, Gary and the team will continue to lead Match Group forward. Thank you, Mandy, for everything."

16:22 EST Satsuma Pharmaceuticals announces results from STS101 trial published - Satsuma Pharmaceuticals announced that Phase 1 trial results detailing pharmacokinetics, or PK, tolerability, and safety with its lead product candidate, STS101 nasal powder for the acute treatment of migraine, have been published online in the official peer-reviewed journal of the American Headache Society, Headache, The Journal of Head and Face Pain. The publication reports results from a Phase 1, open-label, 2-part, active-controlled, 3-period crossover study sponsored by Satsuma and designed to investigate and compare the safety and PK of STS101, DHE liquid nasal spray, and intramuscular, or IM, DHE injection in healthy subjects. Study authors concluded that STS101 showed a favorable tolerability profile and resulted in DHE plasma concentrations comparable to IM DHE and exceeding Migranal. Based on data from this study and the results from other clinical studies with DHE, the authors posited that STS101 is anticipated to demonstrate rapid pain relief, improvement in functionality, and "excellent" 2-hour and sustained pain freedom rates. STS101 is currently being evaluated as an acute treatment for migraine in an ongoing Phase 3 efficacy trial, for which Satsuma expects to report top-line data in the second half of this year. STS101 showed rapid absorption, achieving within 10 minutes the mean DHE plasma concentration threshold that Satsuma estimates to be minimally necessary for efficacy based on prior clinical studies. Drug exposure was substantially greater than Migranal, comparable to IM DHE, and exceeded exposures previously reported for an orally inhaled DHE product candidate (MAP0004) by approximately 30 minutes post-dose and at all subsequent time points. MAP0004 previously demonstrated rapid onset of clinical efficacy and robust anti-migraine efficacy in a large, double-blind, placebo-controlled Phase 3 trial. STS101 PK variability was lower than Migranal, suggesting STS101 may have more predictable, reliable, and robust clinical performance. With STS101, maximum DHE plasma concentrations were sufficiently low so as to avoid nausea or vomiting, which are common side-effects with intravenous DHE. STS101 demonstrated a favorable tolerability profile and all treatment-related adverse events were mild, transient, and related to the nasal route of administration or known effects of DHE.

16:21 EST C.H. Robinson to acquire Prime Distribution Services for $225M from Roadrunner - C.H. Robinson (CHRW) announced it has entered into a definitive agreement to acquire Prime Distribution Services, a leading provider of retail consolidation services in North America, from Roadrunner Transportation (RRTS). The agreement is subject to certain customary closing conditions, including regulatory approval. Prime had $108.7 million in total revenues for the fiscal year ended December 31, 2019. C.H. Robinson intends to purchase Prime for approximately $225 million in cash. The acquisition is expected to be slightly accretive in 2020 and will be financed through cash on hand and funds drawn from C.H. Robinson's existing credit facilities.

16:19 EST C.H. Robinson targets $100M operating expense reduction - The company states: "With a continued focus on lowering our cost to serve and cost to sell, we expect to deliver $100 million in operating expense reduction across the enterprise over the next three years. These initiatives will leverage our technology investments to further optimize our office network and business operations while at the same time continuing to expand the benefits and services we offer to our customers and our carriers. And with nearly 10 million shares still outstanding on our share repurchase authorization, we will continue to opportunistically repurchase our shares to create value for our shareholders."

16:18 EST C.H. Robinson reports Q4 operating margin down 12.2% at 23.6% - Reports Q4 operating cash flow down 19.9% at $211.6M. CEO Bob Biesterfeld says: "Despite a quarter of challenging operating results, I do believe we took important steps in the quarter. Pricing adjustments to reflect the current market enabled us to deliver flat volume in NAST truckload, including a mid-single-digit increase in contractual volume, and 4.5 percent volume growth in LTL, healthy market share gains in a quarter where volumes as measured by the Cass Freight Index declined approximately 6 percent. We are starting to see our increased investments in technology drive operating efficiency in our business, including a 330-basis point favorable spread between truckload volume growth and headcount growth in our NAST business. While our fourth quarter financial results demonstrate that we are not immune to large cyclical swings in the freight environment, we firmly believe that our continued investments through cycles will drive the alignment between net revenue growth and operating costs needed to drive operating margin expansion through freight cycles over the long term."

16:16 EST EMA validates Kite's MAA for KTE-X19 - Kite, a Gilead Company, announced that the company's Marketing Authorization Application for KTE-X19, an investigational chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, has been fully validated and is now under evaluation by the European Medicines Agency. The MAA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented during an oral session at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando.

16:14 EST Skyline reports Q3 backlog $133M vs. $181M last year - Reports Q3 average selling price down 2% at $60.6K.

16:14 EST Bonanza Creek sees FY20 productio of 26.0 - 29.0 MBoe/d - Annual 2020 production guidance of 26.0 - 29.0 MBoe/d, representing 11 - 23% growth over 2019 volumes Total 2020 annual capital expenditures are expected to be $215 - $235 million Eric Greager, President and Chief Executive Officer of Bonanza Creek, commented, "The Company finished 2019 strong, meeting or beating initial guidance for the year and meaningfully improving key performance measures throughout the year. Average sales volumes in 2019 finished near the high-end of initial guidance and increased 48% over 2018, while capex finished below budget, below guidance, and 19% lower than 2018. Improvements in our cost structure continued through 2019, and we expect total opex and cash G&A to be at or below our initial guidance for the year."Greager continued, "We are excited to provide initial guidance and a capital plan for 2020. We expect to deliver production growth of 17% at the mid-point of our guidance range, with capex that is flat to 2019. We continue to work closely with our development partner and remain ready for the start of French Lake drilling in early Q4 2020."

16:12 EST Bonanza Creek reports Q4 average sales volumes 24.3 MBoe/d - Bonanza Creek Energy provided preliminary 2019 results and 2020 guidance. Highlights for fourth quarter and full year 2019 include: Average sales volumes of 24.3 MBoe/d for the fourth quarter 2019; up 37% over fourth quarter 2018 Average sales volumes of 23.5 MBoe/d for full year 2019; up 48% year-over-year, in the top-quartile of the initial 2019 annual guidance and at the mid-point of the most recent guidance Total 2019 capital expenditures are estimated to be $222 million, below the low-end of the most recent guidance of $230 - $240 million and initial guidance of $230 - $255 million

16:10 EST Conatus, Histogen enter into definitive merger agreement - Conatus Pharmaceuticals and Histogen, a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen, and is expected to trade on the Nasdaq Capital Market under a new ticker symbol still to be determined and will focus on advancement of its patented technology for dermatological and orthopedic indications.

16:10 EST Starbucks up 1% to $89.33 after earnings report

16:09 EST Starbucks CEO says 'off to a strong start in fiscal 2020' - "Building on solid business momentum from fiscal 2019, Starbucks performed very well throughout the first quarter, including one of the strongest holiday seasons in the history of our company. As a result, we are off to a strong start in fiscal 2020. Our growth was fueled by a healthy balance of comparable sales growth and new store development, as well as continued expansion of our Global Coffee Alliance with Nestle. Investments in our partners, beverage innovation and digital customer relationships contributed not only to strong topline growth, but also significant margin expansion in the quarter. Our partners are the center of creating a special Starbucks Experience for each and every customer we serve, and I am very grateful for their extraordinary efforts through this holiday quarter. As we begin our fiscal second quarter, I want to acknowledge the dynamic situation our partners in China are navigating as health officials respond to the coronavirus. As events unfold, we will be transparent with all stakeholders in communicating how we are responding to these extraordinary circumstances and the implications for our near-term business results. We remain optimistic and committed to the long-term opportunity in China, building on our brand heritage and 20-year legacy of profitable growth," said Kevin Johnson, president and CEO.

16:08 EST Starbucks says active Starbucks Rewards membership in U.S. up 16% - Starbucks Rewards loyalty program grew to 18.9M active members in the U.S., up 16% year-over-year.

16:07 EST Teva announces FDA approval of Ajovy injection autoinjector - Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries announced that the FDA has approved an autoinjector device for AJOVY, or fremanezumab-vfrm, injection. The AJOVY autoinjector is expected to be available to patients in the coming months.

16:04 EST Teekay Tankers sells three vessels for approximately $57M - The company has agreed to sell three 2003-built Suezmax tankers in separate transactions for combined sale proceeds of approximately $57M. The first vessel was delivered to the buyer in December 2019 and the remaining two vessels are expected to be delivered during February 2020. The proceeds from the vessel sales are expected to be used to reduce debt, including approximately $30M of debt directly secured by these three vessels.

16:03 EST Teekay Tankers sells non-U.S. ship-to-ship transfer business - The company has reached an agreement with Hili Ventures to sell a portion of its oil and gas ship-to-ship transfer support services business, which also provides gas terminal management and gas consulting services, for approximately $26M. The sale is expected to close late in Q1 or early in Q2. Teekay Tankers will retain its entire Full-Service Lightering business that operates in the U.S. Gulf, which provides ship-to-ship oil transfers for both U.S. crude imports and exports. In addition, the Company will continue to operate oil ship-to-ship transfer support services in North America and the Caribbean, a business that has synergies with its core Full-Service Lightering business.

16:00 EST Conatus trading halted, news pending

15:18 EST MoneyGram to create a new bank deposit service in Ukraine - MoneyGram announced that it is partnering with Industrialbank to create a new bank deposit service in Ukraine. MoneyGram is the first company in the industry to enable consumers to send money directly to any receiver's bank account in the country.

14:32 EST Nucor sees peak CapEx over next two years - Asked by an analyst on its Q4 earnings call about its growth CapEx increasing, Nucor CFO James Frias responded that the company is "starting here with a very strong liquidity position with $28 billion in cash and short-term investments." Frias added: "We're going to have to peak the CapEx over the next two years and then it should taper off based on projects we've announced and have in our pipeline actively today. And so we could be slightly cash flow negative over the next two years and then -- but over the next five years, we expect to be strong cash flow positive. So right now, we would not expect to draw on the revolver."

14:10 EST Tessco sinks following 90% dividend cut, Q3 revenue decline - Shares of Tessco are moving lower after the company last night announced a 90% dividend reduction and year-over-year decline in revenue for the third quarter. The company's Q3 revenue totaled $139.6M compared with $152.3M for the same period last year, as a result, according to the company, of lower sales in the Retail segment and VAR and Integrator market. Tessco's board also declared a quarterly cash dividend of 2c per common share payable on February 26, to common shareholders of record on February 12. This represents a decrease of 90% from the dividend of 20c paid in November 2019. During the third quarter, the company conducted a strategic study of the business "with the goal of ensuring that all of the Company's assets and resources are being best utilized to enhance long-term shareholder value. As a result of that study, the Board is reallocating resources to increase investment in the technology and talent required to accelerate the Company's long-term growth. Any future declaration of dividends, and the establishment of record and payment dates, is subject to future determinations of the Board of Directors." Sandip Mukerjee, CEO of Tessco, added, "During the quarter, we completed a strategic study of the business with the goal of best utilizing all of the Company's assets and resources to enhance long-term shareholder value, with a particular focus on ensuring that we are well positioned to capitalize on unprecedented changes in the wireless ecosystem, driven by 5G, Wi-Fi 6 and CBRS....We are nearing the finish of our long-term strategic plan development and look forward to sharing it with you as we head into fiscal 2021." Shares of Tessco are down 21%, or 2.59, to $9.50 in afternoon trading.

13:24 EST Airbus sees EUR 3.6B provision for French, U.K. and U.S. settlement - In the context of the investigations by the French Parquet National Financier, the U.K. Serious Fraud Office and the U.S. authorities, Airbus said it has reached agreement in principle with the authorities. The investigations by the authorities relate to allegations of bribery and corruption and to inaccuracies in filings made with the U.S. authorities pursuant to the U.S. International Traffic in Arms Regulations. The agreement with the SFO was the subject of a preliminary court ruling today and will require final judicial approval in a U.K. court. Furthermore, agreements with the PNF and the U.S. authorities also remain subject to approval by French court and U.S. court and regulator, respectively. The court hearings in France, the U.K. and the U.S. are expected to take place on January 31. If approved by the courts, the agreements will result in Airbus taking a provision of EUR 3.6B for the payment of potential penalties to the French, U.K., and U.S. authorities, which will be booked in Airbus' 2019 accounts. Airbus added that it will continue to cooperate with the authorities.

12:38 EST Carnival suspended cruise operations from Chinese ports until Feb. 4 - Carnival disclosed in a regulatory filing, "In response to the ongoing coronavirus outbreak, China has implemented travel restrictions. As a result, we have suspended cruise operations from Chinese ports between January 25th and February 4th, canceling nine cruises. We also expect that travel restrictions will result in cancellations from Chinese fly-cruise guests booked on cruises embarking in ports outside China. We estimate that this will impact our financial performance by $0.03 to $0.04 per share. If the travel restrictions in China continue until the end of February, we estimate that this will further impact our financial performance by an additional $0.05 to $0.06 per share. Five percent of our capacity was scheduled to be deployed in China in fiscal year 2020. If these travel restrictions continue for an extended period of time, they could have a material impact on our financial performance." Shares of Carnival are up 3% to $46.50 in midday trading.

12:28 EST Renault names former Seat Chairman Luca de Meo as CEO - Renault's board made the decision to appoint Luca de Meo as Chief Executive Officer and Chairman, effective July 1. Clotilde Delbos, Interim Chief Executive Officer of Renault, will continue to assume her functions until Luca de Meo takes office. In addition, the board gave a favorable opinion on her appointment to the position of Deputy Chief Executive Officer, effective July 1. de Meo was Chairman of the Executive Committee of Seat from November 1, 2015 until January 2020 and member of the Supervisory Boards Ducati and Lamborghini, and Chairman of the Board of Directors of the Volkswagen Group in Italy.

12:18 EST Williams boosts quarterly dividend to 40c from 38c - Williams said its board has approved a regular dividend of 40c per share, or $1.60 annualized, on the company's common stock, payable on March 30, to holders of record at the close of business on March 13. This is a 5.3% increase from Williams' Q1 quarterly dividend of 38c per share, paid in March 2019.

12:00 EST Aspen Aerogels falls -10.4% - Aspen Aerogels is down -10.4%, or -$1.03 to $8.84.

12:00 EST Despegar.com rises 11.5% - Despegar.com is up 11.5%, or $1.43 to $13.87.

12:00 EST Leaf Group rises 16.8% - Leaf Group is up 16.8%, or 52c to $3.62.

11:52 EST Lockheed Martin says happy with current portfolio, has 'firepower' to pursue M&A

11:51 EST Facebook's Zuckerberg provides update on privacy changes, says OFA now available - Facebook's CEO Mark Zuckerberg said in a statement that, "Since today is Data Privacy Day, I wanted to share some of the work we've been doing to give you more control over your privacy - on and off Facebook. Over the next few weeks we'll show nearly 2 billion people around the world a prompt encouraging them to review their privacy settings. The prompt will show up in your News Feed and direct you to the Privacy Checkup tool, which we recently updated. This makes it even easier to adjust who can see your posts and profile information, strengthen your account security by turning on login alerts, and review the information you share with apps you've logged in to with Facebook. As of today, our Off-Facebook Activity tool is available to people on Facebook around the world. Other businesses send us information about your activity on their sites and we use that information to show you ads that are relevant to you. Now you can see a summary of that information and clear it from your account if you want to. [...] Facebook Login lets you sign in to other apps and services, like games and streaming platforms, using your Facebook account. To help you keep track of your activity, we rolled out Login Notifications earlier this month. These notifications alert you when you use Facebook Login to sign in to third-party apps to help you stay aware of how your account is being used and edit your settings." Reference Link

11:37 EST Lockheed Martin sees contributing less than $1B to pensions in 2021

11:34 EST J&J says at work on potential preventive coronavirus vaccine - In a post to its corporate website, Johnson & Johnson stated in part: "In just a few short weeks, this new strain of a group of viruses called coronaviruses that was first detected in Wuhan, Hubei province, China, has turned into an outbreak, with almost 3,000 confirmed cases and 80 deaths in China, according to the World Health Organization...Officials are still learning about how it's transmitted and its source, but one thing is clear: working fast to stop this virus is critical. To help stay ahead of a potential pandemic, Johnson & Johnson has mobilized quickly to initiate a project to develop a preventive coronavirus vaccine with the potential to protect people against the disease." Reference Link

11:22 EST Lockheed Martin CEO says has 374 aircraft in F-35 backlog

11:10 EST Lockheed Martin sees finalizing 14th F-35 contract lot in early 2020 - Sees F-35 costs falling below $78M with Lot 14.

10:26 EST Aemetis awarded $14M in energy efficiency grants - Aemetis announced that its subsidiary Aemetis Advanced Fuels Keyes has received from the California Energy Commission two grants for a combined total of $14M to implement upgrades that would reduce natural gas use, lower greenhouse gas emissions, decrease operating costs, and reduce the carbon intensity of fuel grade ethanol produced at the Keyes plant. The cost reduction and revenues increase associated with the upgrades are expected to improve the operating cash flow of the Keyes plant by $13M each year.

10:00 EST Inspire Medical falls -6.0% - Inspire Medical is down -6.0%, or -$4.67 to $73.89.

10:00 EST K12 falls -7.6% - K12 is down -7.6%, or -$1.48 to $18.10.

10:00 EST Cellcom Israel rises 10.0% - Cellcom Israel is up 10.0%, or 32c to $3.53.

09:45 EST Harley-Davidson board is 'always mindful' of shareholder value

09:41 EST HDFS sees slight increase in credit losses in FY20 but offset by revenues

09:39 EST Nymox integrating safety data from BPH trials, Prostate Cancer study for NDA - Nymox Pharmaceutical provided a current January 2020 update on several important corporate activities and achievements since the last update in October 2019. The Company recently received the necessary information regarding the formatting and content of its upcoming regulatory filings for its Fexapotide Triflutate first in class injectable drug to treat the symptoms of prostate enlargement in men. The Company is proceeding to integrate safety data from its four Phase I and Phase II BPH clinical trials as well as the safety data from Prostate Cancer Study NX03-0040 into the final dataset that will be part of the New Drug Application submission. The filings seeking approvals in the US and in Europe are now targeted for the first half of 2020 in both jurisdictions. At this point, the Company does not have any barriers to report and does not expect any delays. Nymox is further pleased to report that another peer review publication was recently accepted and published in Research and Reports in Urology. This publication discusses the selective cellular ablation capabilities of Fexapotide Triflutate to induce apoptosis in prostate glandular cells which are a major part of the prostate enlargement which defines benign prostatic hyperplasia. Selective pharmaco-ablation is achieved while leaving the nerve cells and urethra and other nearby tissues unaffected. In fact, the Company has previously reported a statistically significant improvement in sexual function reported by men treated with FT for BPH in its U.S. Phase III long-term follow up studies. A fourth new and important peer review article is expected to appear in the near term. Further information will be provided when the new article appears. The new peer review article reported in January 2020 and published in Research and Reports in Urology provided detailed documentation of the selective pharmco-ablation mechanism of action of FT, demonstrating the highly selective reduction of prostate cells which comprises one of the most important underlying reasons for the highly superior safety and efficacy of Fexapotide. A review article on the progress in the development of Fexapotide entitled "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia" was published in Therapeutic Advances in Urology.

09:35 EST 3M says received grand jury subpoena in December 2019 - Says U.S. Attorney issued a grand jury subpoena in December 2019 related to discharges from its Alabama facility. Says cooperating with inquiry.

09:34 EST GNC Holdings signs multiyear partnership with Jay Glazer - GNC announced a strategic partnership with Jay Glazer, NFL insider and analyst for Fox Sports, MMA coach/trainer and owner of Unbreakable Performance Center. The company said," GNC's expertise in nutritional science and an established supply chain of quality ingredient sources, combined with Glazer's passion and immense background in fitness and training, makes this an unstoppable duo. Together, they will inspire people to find their inner champion and achieve personal success to get well, stay well and live well."

09:30 EST Harley-Davidson Financial Group will adopt CECL in FY20

09:26 EST Harley-Davidson now giving revenue guidance instead of shipment guidance - Management says revenue is a better indicator of performance.

09:20 EST InterDigital 'applauds' launch of Halcyon Principles for connected technologies - InterDigital announced its praise for the release of the Halcyon Principles, a set of guidelines for the ethical development of modern digital technologies. InterDigital served as the principal sponsor of the new industry-focused best practices, presented by Halcyon to help guide digital technology companies in building trust among stakeholders and continuity across industries around intelligent technologies. The Halcyon Principles were developed as the result of a two-day dialogue with leaders from across the U.S. government industry, civil society, academics, and think tanks to create a set of guidelines to help maximize the societal benefits and mitigate any risks associated with the deployment of integrated digital technologies. The principles outline four steps digital technology companies of any size and at any stage of business development can use to engage in the creation and deployment of connected intelligent technologies, while addressing privacy, competition, and other concerns. Namely, the principles offer important guidance around performance accountability, consumer safety, privacy and security, ensuring positive benefits to society, and interoperability and competitiveness.

09:18 EST Park National increases quarterly dividend to $1.02 per share - Park's board of directors authorized a special cash dividend of $0.20 per common share, and increased the quarterly cash dividend to $1.02 per common share. Both dividends are payable on March 10, 2020 to common shareholders of record as of February 21, 2020.

09:18 EST Harley-Davidson sees continued headwinds in U.S. retail sales - Management sees continued headwinds in U.S. retail sales with full-year retail sales in-line with company expectations. Management is confident in More Roads plan. Comments taken from Q4 earnings conference call.

09:12 EST Discover names Amir Arooni as CIO - Amir Arooni, a global banking technology professional with 30 years of experience, has been named Discover's (DFS) new chief information officer, or CIO, responsible for the company's technology organization. He will join the company's executive committee as an executive VP April 2. Arooni, currently is CIO for NN Group (NNGRY) in the Netherlands, which was spun off by ING in 2014. At NN Group, he has led a digital technology transformation for the banking, insurance and asset-management firm. He is responsible for the company's technology function and business information security, among others and the NN Group's integration of the recently acquired insurance and banking company Delta Lloyd.

09:10 EST Griffin announces closing on mortgage loan - Griffin Industrial Realty announced that Riverbend Upper Macungie Properties I LLC and Riverbend Crossings III Holdings, each wholly owned subsidiaries of Griffin, entered into a promissory note providing for a $15M loan, secured by a nonrecourse mortgage given by Riverbend Upper Macungie Properties I LLC on an approximately 134,000 square foot industrial/warehouse building and a nonrecourse mortgage given by Riverbend Crossings III Holdings LLC on an approximately 120,000 square foot industrial/warehouse building. Both buildings are in the Lehigh Valley of Pennsylvania. The Promissory Note, issued by the Borrowers to State Farm Life Insurance Company, has a fixed interest rate of 3.48% and ten-year term, with principal payments based on a twenty-five-year amortization schedule. Approximately $3.2M of the proceeds from the Mortgage Loan were used to repay a maturing mortgage loan on 871 Nestle Way. The balance of the Loan Proceeds will be used for general corporate purposes, including investment in real estate assets.

09:07 EST Gogo announces launch of new DRM service - Gogo announced the upcoming launch of a new digital rights management, or DRM, service that enables playback of video-on-demand content in the most popular browsers without additional plug-ins or app downloads. Developed in partnership with castLabs, the new solution allows each title to be packaged for browsers like Safari and Chrome on all operating systems with a single file using the latest file format in the industry. The single encrypted file format allows for Gogo's inflight entertainment, or IFE, service, Gogo Vision, to maximize the airlines library size and store 50% more content than other solutions. The roll-out of this new technology will be complete in the first half of 2020.

09:06 EST 3M CEO says China, auto, electronics markets remain challenging - Comments taken from the Q4 earnings conference call.

09:04 EST Navient announces agreement to repurchase shares from Canyon Partners affiliates - Navient Corporation announced that it has entered into an agreement to repurchase 20,346,464 shares of common stock owned by certain Canyon Partners, LLC affiliates at a purchase price of $14.77 per share. Navient previously announced a share repurchase program under which it is authorized to repurchase up to $1B of Navient's outstanding common stock. As a result of the shares already repurchased in the open market and this agreement with Canyon, Navient will have approximately $674M in remaining share repurchase authority. Navient continues to expect its total 2020 share repurchase to be broadly in line with 2019 repurchases and the remaining repurchases are likely to be conducted throughout the year. The price of the shares repurchased from Canyon's affiliates equals the closing price of Navient stock on Jan. 27, 2020. Upon completion of the sale, Canyon will no longer hold Navient stock.

09:03 EST QuickLogic to cut workforce by 30% as part of restructuring plan - QuickLogic announced a restructuring plan that will significantly lower its annual operating expenses. When fully implemented by the Q2, the Company estimates the reductions will result in annualized operating expense savings of approximately $4.0M. These changes are expected to only have a minimal impact on the Company's research and development efforts to support planned products and technologies. The majority of the restructuring will come from personnel reductions, which will be across all parts of the Company and geographies, reducing total personnel by approximately 30% by the end of the Q1. The Company estimates it will incur approximately $600,000 of restructuring expenses, of which approximately $500,000 will be cash expenditures with the majority coming in the Q1.

09:03 EST Precipio, TrialJectory form partnership for cancer treatment - TrialJectory, an AI-powered technology platform that empowers cancer patients to search and match with clinical trials, removing barriers to advanced treatment options, announced that the company has launched a new partnership with specialty cancer diagnostics company Precipio to provide cancer patients worldwide with a first-of-its-kind diagnostic and clinical trial-matching service that assists doctors in providing the best possible treatment for their patients. With this partnership, Precipio's comprehensive diagnostic result reports will now include a personalized list of relevant clinical trials matched to the patient based on the trials' eligibility requirements, which are generated by TrialJectory's AI-based clinical trial-matching platform. The platform uses patient clinical information to facilitate the clinical trial search, matching and enrollment by patients and their physicians. If patients decide to further explore one or more of the matched trials, TrialJectory facilitates, on behalf of the patient, all communication with the clinical trial lead, including document collection, appointment scheduling and more.

09:01 EST Arthur J. Gallagher acquires Hanover Excess & Surplus, terms not disclosed - Arthur J. Gallagher & Co. announced the acquisition of Wilmington, N.C.-based Hanover Excess & Surplus. Terms of the transaction were not disclosed. Established in 1970, Hanover Excess & Surplus is a regional managing general agency offering hard-to-place coastal commercial and personal property/casualty coverages, as well as professional liability coverages, to clients across North Carolina, South Carolina, Virginia and Georgia.

08:47 EST Perspecta awarded $277M prime contract to support U.S. Department of Labor - Perspecta announced that it has been awarded a prime contract from the U.S. Department of Labor, Office of the Assistant Secretary for Administration and Management, Office of the Chief Information Officer for operations and maintenance support of the enterprise general support system. The program, which represents new work for the company, has a one-year base with six one-year option periods and a potential value of $277M. Under the program, Perspecta will provide DOL OCIO with enterprise operations and maintenance support services to manage, operate and secure a diverse set of IT infrastructures, applications, services and technology-enabled solutions. Work will support more than 4,000 end users in the DOL's OASAM OCIO headquarters office in Washington, D.C. and 16,000 end users throughout the United States.

08:42 EST Milestone Scientific announces report supporting CompuFlo for PNB procedures - Milestone Scientific announced a report by Olivier Choquet, an expert on peripheral nerve blocks, or PNB, and a consultant to Milestone Scientific, which concludes that the CompuFlo with dynamic pressure sensing technology is the only available device capable of precisely measuring, displaying, warning, controlling and recording needle tip pressure in real time to help reduce the risk of needle injury during PNB procedures. Continuous peripheral nerve block procedures are becoming more prevalent, including pain management for patients undergoing upper/lower extremity surgeries and patients suffering from trauma. Additionally, peripheral nerve blocks are increasingly utilized as an alternative to opioids for pain management, including orthopedic surgeries, which are considered one of the most painful surgeries. Olivier Choquet is the medical director of the emergency surgery operating theater and a medical doctor in the Department of Anesthesiology in Traumatology and Orthopedics, Lapeyronie University hospital, Montpellier, France. In 2015, Choquet and his colleagues at Lapeyronie University hospital started exploring the use of the CompuFlo technology for PNB procedures to assess the optimal flow rate during PNB procedures. He went on to investigate using Dynamic Pressure Sensing technology as a means of detecting direct needle-to-nerve contact using CompuFlo, which he demonstrated. This initial research gave rise to the pursuit of developing a true multimodal monitoring concept of combining ultrasound guidance, nerve stimulation and CompuFlo dynamic pressure sensing technology. A formal comparative clinical study has been conducted and is currently in review for publication in a well-respected, peer-reviewed medical journal.

08:37 EST OncoSec issues shareholder letter in response to Alpha Holdings press release - OncoSec issued the following statement to its shareholders regarding Alpha Holdings January 27 press release: "Alpha's press release about a "revised binding term sheet" provided to OncoSec is disingenuous and misleading. Nothing has changed about Alpha's so-called "proposal" aside from the expiration date. Alpha previously put a 2.5 day expiration on its "proposal." Now, after waiting nearly two weeks, Alpha is resurfacing the exact same proposal, except now with a four-day expiration period. This is meaningless and does nothing to change the poor terms Alpha is purporting to offer shareholders, which a special committee of independent directors and the Company's Board of Directors previously considered and rejected. Institutional Shareholders Services Inc. (ISS), a leading independent proxy advisory firm, considered Alpha's "proposal" and reaffirmed its original recommendation that shareholders vote FOR the proposed strategic investment by, and partnership with, CGP and Sirtex1 (the "CGP/Sirtex Transaction"), noting concerns with "the risks associated with this competing offer," including potential significant dilution of shareholders and "disruption associated with resignations of the CEO and chairman without proposed immediate replacements."2 As we detailed in our January 21st letter to shareholders (see this link), there are numerous reasons why Alpha's "proposal" is filled with holes and contingencies, and is based on questionable motives. For the sake of brevity, we won't repeat those reasons here, but please read our last letter for details. Alpha's press release today is not surprising. We predicted as much when we stated in our shareholder letter last week that "Alpha's 'proposal' is the sort of tactic we EXPECT to see more of from them in the next few weeks, as it seems that they are doing anything and everything they can to derail the CGP/Sirtex Transaction. Do not let their games distract you from the facts." Shareholders deserve a fair meeting, in which all their votes cast are counted. Voting on the WHITE proxy card - whether you support the CGP/Sirtex Transaction or not - will ensure your selection is counted. If you have already voted on the WHITE proxy card, there is no need for you to take any further action at this time."

08:36 EST Syros Pharmaceuticals doses first patient in SY-5609 Phase 1 clinical trial - Syros Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 inhibitor. The trial is enrolling patients with advanced breast, colorectal, lung or ovarian cancer, or with solid tumors of any histology that harbor Rb pathway alterations.

08:35 EST Colliers International names John Friedrichsen COO, Christian Mayer CFO - Colliers International announced changes to its global executive team, effective immediately. John Friedrichsen, currently CFO, will step into the newly created global leadership position of COO. In this role, Friedrichsen will provide executive oversight and leadership at the global level for a number of growth initiatives including strengthening our Occupier Services, Corporate Solutions and Capital Markets businesses, with a particular focus on driving further internal growth and greater collaboration among the established teams across the business globally. Christian Mayer, currently serving as SVP, Finance & Treasurer, has been appointed CFO. Friedrichsen and Mayer will report directly to Jay Hennick, Global Chairman & CEO.

08:34 EST HCA Healthcare board authorizes additional $2B stock buyback - The HCA Healthcare board has authorized an additional share repurchase program for up to $2B of the company's outstanding common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.

08:33 EST Cheniere Energy Partners increases quarterly distribution to 63c per unit - Cheniere Energy Partners declared a cash distribution per common and subordinated unit of 63c to unitholders of record as of February 7 and the related distribution to its general partner. All of these distributions are payable on February 14.

08:33 EST Avis Budget adopts short-term shareholder rights plan - Avis Budget Group announced that a committee of its Board of Directors that was formed to manage the Board's engagement with SRS Investment Management has unanimously approved the adoption of a one-year shareholder rights plan to protect the best interests of Avis Budget Group and all of its shareholders. The rights plan is intended to prevent SRS, the Company's largest shareholder, from obtaining effective control of Avis Budget Group without paying a control premium. The rights plan is designed to ensure that all Avis Budget Group shareholders have a fair opportunity to vote on the future of the Company at the upcoming 2020 Annual Meeting of shareholders. SRS has disclosed a 33.8% economic interest in Avis Budget Group, including ownership over 21.9% of the outstanding shares and economic exposure to an additional 11.9% of the outstanding shares through derivative instruments. The standstill provisions under the Company's 2018 cooperation agreement with SRS expire on January 28, 2020. The Committee in recent months has made numerous good-faith attempts to reach a new agreement with SRS, but SRS has been unwilling to agree to terms acceptable to the Committee. In light of SRS's unwillingness to enter into a new cooperation agreement on terms acceptable to the Committee and its current ownership level and Board representation, the Committee determined that the adoption of a tailored, short-term rights plan is necessary to protect Avis Budget Group and its other shareholders. If SRS agrees to enter into a new cooperation agreement on mutually acceptable terms, the Committee will authorize the immediate termination of the rights plan. The Board adopted similar short-term rights plans in January 2017 and January 2018, when SRS was unwilling to renew prior expiring standstill provisions. The Board terminated those rights plans immediately when it and SRS reached renewed cooperation agreements. The rights plan is in place for a one-year duration, expiring on January 26, 2021. Should the rights plan be extended or renewed, such extension or renewal will be put to a shareholder vote. The rights plan may also be terminated, or the rights may be redeemed, prior to the scheduled expiration of the rights plan by the Board under certain other circumstances.

08:31 EST Vonage selected by Educational Services Commission of New Jersey - Vonage has been awarded an RFP to provide Voice, Unified Communications and Collaboration Solutions to The Educational Services Commission of New Jersey, or ESCNJ, membership, which includes more than 1,300 public agencies throughout the state of New Jersey. ESCNJ chose Vonage as a cloud communications provider. ESCNJ works in partnership with New Jersey school districts to coordinate cost-efficient purchasing opportunities for educational institutions and municipalities to limit the tax burden on New Jersey residents.

08:27 EST Starboard Value granted FTC early termination for deal with Box - A post to the website of the Federal Trade Commission shows that Starboard Value and Opportunity Fund was granted early termination of the FTC's review period for the fund's transaction with Box Inc. Reference Link

08:20 EST CommAgility, NXP Semiconductors collaborate for 5G New Radio platform - CommAgility, a Wireless Telecom Group company (WTT), announced that it has collaborated with NXP Semiconductors (NXPI) in connection with their recently-announced Layerscape Access LA12XX Programmable Baseband Processors for 5G New Radio processing. The collaboration enables CommAgility to accelerate 5G hardware and software development and enhance the performance of its 5G platform, providing significant advantages to customers and reducing their time to market. CommAgility will use its 5G platform to create private and specialized network solutions based on NXP programmable baseband processors. The collaboration will help CommAgility address the anticipated 5G long-term growth opportunity and both companies will work together to meet customer requirements and provide unique, competitive solutions.

08:16 EST Albemarle named to S&P 500 Dividend Aristocrats Index - Albemarle announced that effective Feb. 3, the company will be named to the S&P 500 Dividend Aristocrats Index. The Index measures the performance of S&P 500 companies that have increased dividends every year for the last 25 consecutive years.

08:15 EST Envision Solar files patent application for wireless/inductive charging EV ARC - Envision Solar International announces the filing of U.S. Patent Application No. 16/719,634 with the United States Patent and Trademark Office for its new wireless-capable EV ARC product. The patent pending Inductive EV ARC will have the capability of charging EV vehicles via a wireless receiver without plugging the vehicle in with a charging cable

08:12 EST Sunergy Solar using Enphase Energy's products to install solar - Enphase Energy announced that Sunergy Solar uses Enphase Energy products to install high-quality solar, faster and provide a great homeowner experience by making full use of the Enphase Enlighten monitoring and service platform.

08:11 EST CytoDyn says leronlimab under evaluation as potential coronavirus treatment - CytoDyn announced that it is exploring leronlimab as a potential treatment for patients infected with the 2019 Novel Coronavirus, a rapidly spreading virus and potential worldwide emergency. Leronlimab has shown no drug-related serious adverse events in nine clinical trials with more than 800 patients and has been previously used in combination with protease inhibitors used in HIV therapy, which could be potentially used to treat the specific strain of the 2019-nCoV.

08:09 EST HTG Molecular receives European patent grant notification for DLBCL subtyping - HTG Molecular Diagnostics announced it has received notification of validation of European patent number EP 3356554 for its methods for subtyping diffuse large B-cell lymphoma, effective October 2019. HTG was previously granted a patent for this technology in the United States in 2018.

08:08 EST Iridium says Iridium CloudConnect now actively serving customers - Iridium (IRDM) announced that Iridium CloudConnect, the first and only satellite cloud-based solution offering truly global coverage for Internet of Things applications, is now actively serving customers. This new service combines Iridium IoT capabilities with Amazon Web Services (AMZN) IoT and cloud services extending customers' IoT reach to the more than 80% of the Earth that lacks terrestrial coverage.

08:07 EST Aeterna Zentaris completes patient recruitment in pediatric study of Macimorelin - Aeterna Zentaris announced the successful completion of patient recruitment for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of growth hormone deficiency in children. This study, AEZS-130-P01, is the first of two studies as agreed with the European Medicines Agency in the Company's Pediatric Investigation Plan for macimorelin. Macimorelin, a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. The goal of Study P01 is to establish a dose that can both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD. The recommended dose derived from Study P01 will be evaluated in the pivotal second study AEZS-130-P02 on diagnostic efficacy and safety. Study P01 is an international, multicenter study which is being conducted in Hungary, Poland, Ukraine, Serbia, and Russia. Study P01 is an open label, group comparison, dose escalation trial designed to investigate the safety, tolerability, and pharmacokinetic/pharmacodynamic of macimorelin acetate after ascending single oral doses of macimorelin at 0.25, 0.5, and 1.0 mg per kg body weight in pediatric patients from 2 to less than 18 years of age with suspected GHD. The Company enrolled a total of 24 pediatric patients across the three cohorts of the study. Per study protocol, all enrolled patients will complete four study visits after successful completion of the screening period. At Visit 1 and Visit 3, a provocative GH stimulation test will be conducted according to the study sites' local practices. At Visit 2, the macimorelin test will be performed: following the oral administration of the macimorelin solution, blood samples will be taken at predefined times for PK/PD assessment. Visit 4 is a safety follow-up visit at study end.

08:07 EST Raytheon awarded $403M U.S. Navy contract - Raytheon was awarded a $403M System Demonstration Test Articles contract with the U.S. Navy for Next Generation Jammer Mid-Band. The SDTA pods will be delivered to the fleet once developmental and operational testing is complete.

08:06 EST comScore and Rural Media Group announce deal for two TV networks - Comscore and Rural Media Group, a portfolio of media outlets, announced a multi-year deal for two of its flagship television networks, The Cowboy Channel and RFD-TV.

08:05 EST Outlook Therapeutics announces agreement to regain ownership of ONS-5010 profits - Outlook Therapeutics has entered into agreements with BioLexis, its largest stockholder, and MTTR, its development partner for ONS-5010, to better align the interests of all parties with the Company's common stockholders and support the continued development of ONS-5010. On January 27, 2020, the Company and MTTR executed a termination agreement and mutual release providing for termination of the existing current strategic partnership agreement between the Company and MTTR, thereby eliminating any rights that MTTR had to potential future royalty payments based on net proceeds from licensing arrangements and future net sales of ONS-5010. In exchange, the Company agreed to issue an aggregate of approximately 7.2 million shares of common stock to the four principals at MTTR, subject to approval by the Company's stockholders, and the Company entered into consulting agreements directly with each of the four MTTR principals setting out the terms of their respective compensation arrangements and transfer restrictions and repurchase rights that will apply to the shares when issued. The termination agreement and mutual release and the consulting agreements will be effective upon stockholder approval of the share issuance. Terry Dagnon and Jeff Evanson will continue to operate in their roles as Chief Operating Officer and Chief Commercial Officer, respectively, and Dr. Mark Humayun will continue in his role as Medical Advisor. The Company intends to seek the requisite stockholder approval to issue the shares of common stock at its 2020 Annual Meeting of Stockholders to be held on March 19, 2020. With the termination of the existing MTTR strategic partnership agreement, the Company will own 100% of any potential licensing proceeds or net sales that may be generated from ONS-5010. On January 27, 2020, the Company entered into an agreement with BioLexis whereby the Company agreed to seek stockholder approval to amend the terms of its outstanding Series A-1 convertible preferred stock in exchange for BioLexis' agreement to convert all of its 68,112 shares of Series A-1 Preferred outstanding promptly after such terms are amended. The proposed amendment of the Series A-1 Preferred will, if approved, increase the conversion rate to approximately $431.03 per share and would result in 29,358,621 shares issuable upon conversion of the 68,112 shares of Series A-1 Preferred outstanding. The proposed terms also clarify that while the Series A-1 Preferred vote on an as-converted basis, for voting purposes the Series A-1 Preferred will use a modified conversion rate tied to the "Minimum Price" on January 27, 2020 in order to comply with applicable Nasdaq rules. The Company intends to seek the requisite stockholder approval to amend the terms of the Series A-1 Preferred and issue the shares of common stock upon conversion thereof pursuant to the amended terms at its 2020 Annual Meeting of Stockholders to be held on March 19, 2020. In connection with this Agreement, BioLexis has agreed to promptly convert the Series A-1 Preferred to common stock following the effectiveness of the amendment of the Series A-1 Preferred. The amendment of the Series A-1 Preferred and subsequent conversion thereof continues the Company's efforts to eliminate outstanding securities with preferential redemption features, dividend payments and other rights not available to common stockholders. On January 27, 2020, the Company and BioLexis agreed to reduce the exercise price to $0.232 per share on warrants to acquire 4,657,852 shares of common stock held by BioLexis in exchange for BioLexis' agreement to promptly exercise such warrants for cash. The warrant exercise will result in cash proceeds to the Company of $1,080,682. This warrant amendment and cash exercise completes the Company's efforts begun in December 2019 to significantly reduce its outstanding warrants. Upon completion of the exercise of these warrants, the Company will have remaining warrants outstanding exercisable for approximately 0.9 million shares of common stock.

08:04 EST Nucor CEO says 'confident that our positive momentum will continue in 2020' - "Stronger than expected steel mill segment performance in December was the primary driver for higher actual fourth quarter earnings than we indicated in our mid-December quantitative guidance," said Leon Topalian, Nucor's President and CEO. "We believe that the inventory destocking that occurred throughout most of 2019 concluded in the fourth quarter, when customers resumed more normal buying patterns. Additionally, general business conditions improved in the fourth quarter due to a number of factors, including a rate cut by the Federal Reserve, the new labor agreement between the United Automobile Workers and GM, and definitive progress on the trade front. For the full year, strong performance in many of our steel products businesses partially offset the impact of destocking on our steelmaking operations. In particular, our Vulcraft/Verco and Building Systems groups both achieved record profitability in 2019, reflecting both strong execution by our teammates and favorable nonresidential construction market conditions. We are encouraged by recent economic trends and confident that our positive momentum will continue in 2020. I would like to thank Nucor's dedicated teammates across the company for their continued focus on safety, serving our customers and creating value for shareholders."

08:03 EST CNS completes pilot run of the recrystallization of the Reata API - CNS Pharmaceuticals announced that Anthem Biosciences of Bangalore, India, has completed a pilot run of the recrystallization of the Reata Pharmaceuticals API. It has also completed a lyophilization of the API. Samples of the drug product, which include 299 capped vials, have been shipped to Intertek Pharmaceutical Services for further analysis and release. As previously announced, the FDA agreed in a preclinical submission that CNS could use Reata API as long as it was reprocessed and released under GMP conditions, and that the new lyophilized form of the drug product could be used during the Company's upcoming clinical trial.

08:02 EST EXL appoints Maurizio Nicolelli as EVP, CFO - EXL (EXLS) announced the appointment of Maurizio Nicolelli to the role of EVP and CFO effective February 3, 2020. Mr. Nicolelli will join EXL's Executive Committee and will be based at EXL's corporate headquarters in New York. Nicolelli's most recent role was Senior Vice President and Chief Financial Officer of Casa Systems (CASA), which he joined in 2019. Effective February 3, 2020, Pavan Bagai will resign his role as interim CFO, and will continue in his role as President and COO.

07:46 EST CalAmp subsidiary teams up with Volkswagen Financial Services Mexico - CalAmp announced its subsidiary, LoJack Mexico, is teaming with Volkswagen Financial Services Mexico to enrich its Full-Service Leasing offerings with real-time vehicle tracking, diagnostics and driver behavior insights. Over the coming year, LoJack Mexico's state-of-the-art telematics will be installed in select light, heavy-duty, and long haul trucks and buses leased through more than 300 VWFS clients across Mexico. These new features will enable fleet managers to increase operational efficiencies, minimize the risk of theft and improve driver safety when leasing vehicles through VWFS.

07:36 EST Primoris announces pipeline awards valued over $260M - Primoris Services Corporation announced new pipeline awards with a combined value over $260M. The contracts were secured by Rockford and Primoris Field Services, both part of the Pipeline and Underground segment. The awards are for a combined 148 miles of various size pipelines, ranging from 6" to 36", and are located in New Mexico and Texas. All work is scheduled to commence in the first quarter of 2020 and to be completed in the third quarter of 2020.

07:34 EST OpGen, Curetis schedule special meetings for approval of business combination - OpGen announced that a key milestone has been accomplished in the proposed business combination with Curetis. On January 27, 2020, OpGen filed and furnished to its stockholders a proxy statement/prospectus and a notice of special meeting of OpGen stockholders, to be held on March 10, 2020 at 10:00am ET at the offices of Ballard Spahr LLP, 1909 K Street, NW, 12 th Floor, Washington DC. At the special meeting, OpGen is seeking shareholder approval of the business combination of OpGen and Curetis. Curetis will host its shareholder meeting on the same day at 1:00pm CET with the same objective. The Curetis extraordinary general meeting will take place at Steigenberger Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. Successful votes of the shareholders of the respective companies are the last remaining major steps towards closing of the transaction.

07:33 EST Incyte announces TRuE-AD2 study meets primary endpoint - Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients with atopic dermatitis, or AD. The study, part of the TRuE-AD clinical trial program, met its primary endpoint. Significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator's Global Assessment Treatment Success, or IGA-TS, than patients treated with vehicle control. The overall efficacy and safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed. The long-term safety portion of the study will continue as planned. Data from TRuE-AD2 will be submitted for presentation at an upcoming scientific meeting.

07:32 EST Lockheed Martin announces record backlog of $144B at end of 2019

07:12 EST Pfizer CFO says 'pleased with our 2019 financial results' - Frank D'Amelio, CFO and Executive Vice President, Business Operations and Global Supply, stated, "I am pleased with our 2019 financial results, which met or exceeded all components of our financial guidance. Our Biopharma business generated 8% operational revenue growth, driven by strong growth from Ibrance, Eliquis, Xeljanz and Vyndaqel/Vyndamax. As expected, the Upjohn business declined 16% operationally, primarily reflecting the U.S. loss of exclusivity of Lyrica in July 2019. Excluding Lyrica in the U.S. and the impact of other recent product losses of exclusivity, Upjohn revenues declined 3% operationally in 2019. We also returned $16.9 billion directly to shareholders through share repurchases and dividends, demonstrating our continued commitment to returning capital to our shareholders. Today we also provided 2020 financial guidance for Total Company, New Pfizer and Upjohn. The midpoint of the revenue guidance range for New Pfizer implies 8% operational growth and reflects anticipated continued strong growth from certain in-line brands such as Ibrance, Eliquis, Xeljanz, Xtandi and Inlyta, from recent and expected product launches such as Vyndaqel/Vyndamax, Braftovi, Mektovi and oncology biosimilars as well as from emerging markets. Since July 2019, several of the aforementioned products have performed better than we had anticipated and have generated strong momentum that we expect to continue in 2020. The midpoint of the revenue guidance range for Upjohn implies a 23% operational decline, primarily reflecting expected declines for products that have recently lost marketing exclusivity and lower revenues from China due to the geographic expansion of the volume-based procurement program to all Chinese provinces in 2020. Importantly, the financial guidance for Upjohn remains unchanged on an operational basis from the preliminary financial targets that were provided in July 2019."

07:08 EST Alkermes says FDA accepts ALKS 3831 NDA for review, assigns Nov. 15 PDUFA date - Alkermes announced that the U.S. Food and Drug Administration has accepted for review the company's New Drug Application, or NDA, seeking approval of ALKS 3831 for the treatment of schizophrenia and for the treatment of bipolar I disorder. ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The NDA has been assigned a Prescription Drug User Fee Act, or PDUFA, target action date of Nov. 15, 2020. "The acceptance of the NDA for ALKS 3831 marks an important milestone toward our goal of offering a new treatment option to people living with schizophrenia or bipolar I disorder. The ALKS 3831 development program builds on Alkermes' commitment to developing new therapeutic options that seek to address unmet needs of patients in large therapeutic areas. We believe ALKS 3831 has the potential to be a meaningful new offering for patients with these serious and complex mental health disorders, and we look forward to engaging with the FDA throughout the NDA review process," said Craig Hopkinson, M.D., Chief Medical Officer at Alkermes.

07:07 EST CommScope receives FCC approval for full commercial deployment of CBRS - CommScope has received official notification from the Federal Communication Commission, or FCC, that its spectrum access system, or SAS, to support 3.5 GHz citizens broadband radio service, or CBRS, is now approved for full commercial deployment. With this announcement, CommScope's SAS will become a foundation to open up 150 MHz of CBRS spectrum that until now had very limited use. With the FCC Public Notice DA-20-110A1, organizations from mobile network operators and neutral host network operators to private enterprises, WISPS, and municipalities will be able to put CBRS to use for a wide range of applications, including mobile, fixed wireless access, IoT, small cell deployments and in-building cellular and private LTE networks.

07:04 EST RTI Surgical expects to close sale of OEM business in 1H20 - RTI Surgical Holdings announced that it has set the record date for the special meeting of its shareholders to, among other things, consider and vote on various proposals necessary to close the previously announced Equity Purchase Agreement, dated January 13, 2020, with Ardi Bidco Ltd., a Delaware corporation and an entity affiliated with Montagu Private Equity, LLP , pursuant to which the Buyer will acquire the OEM business of the Company by means of a sale of certain affiliates of the Company. Stockholders of record as of the close of business on February 25, 2020, will be entitled to vote at the special meeting, which is scheduled to take place on March 31, 2020. The Sale is subject to certain customary closing conditions and approval from our stockholders. The Sale is expected to close in the first half of 2020.

07:04 EST Armata Pharmaceuticals, Innoviva announce $25M investment - Armata Pharmaceuticals (ARMP) and Innoviva (INVA) announced that they have entered into a securities purchase agreement pursuant to which Innoviva will purchase, upon satisfaction of certain closing conditions, approximately $25M in Armata common stock and warrant securities. Armata expects to use the proceeds from the offering to support the ongoing advancement of its bacteriophage development programs, including the expected first in human studies related to Armata's lead phage candidate, AP-PA02, targeting Pseudomonas aeruginosa, as well as AP-SA02, its phage candidate targeting Staphylococcus Aureus. Subject to the satisfaction of certain closing conditions, including, with respect to the second closing, the approval of Armata's stockholders, the transactions contemplated by the securities purchase agreement are expected to close during the first quarter of 2020.

07:03 EST LiveRamp, TripleLift partners to bring addressability to open web - TripleLift has partnered with LiveRamp. With this partnership, marketers will be able to leverage native creative executions with enhanced addressability for targeting and measurement capabilities on the open web, matching the quality and performance of walled gardens. For publishers, identity resolution promises to unlock a great share of digital ad spend. TripleLift's integration of LiveRamp IdentityLink a person-based identifier now empowers marketers to deliver their custom native ads across the TripleLift Exchange with the same quality and performance as within the walled gardens.

07:01 EST Alkermes announces FDA approved NDA for ALKS 3831 - Alkermes announced that the FDA has accepted for review the company's New Drug Application, or NDA, seeking approval of ALKS 3831, or olanzapine/samidorphan, for the treatment of schizophrenia and for the treatment of bipolar I disorder. ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The NDA has been assigned a Prescription Drug User Fee Act, or PDUFA, target action date of Nov. 15. "The acceptance of the NDA for ALKS 3831 marks an important milestone toward our goal of offering a new treatment option to people living with schizophrenia or bipolar I disorder. The ALKS 3831 development program builds on Alkermes' commitment to developing new therapeutic options that seek to address unmet needs of patients in large therapeutic areas," said Craig Hopkinson, Chief Medical Officer at Alkermes. "We believe ALKS 3831 has the potential to be a meaningful new offering for patients with these serious and complex mental health disorders, and we look forward to engaging with the FDA throughout the NDA review process."

06:56 EST Halliburton wins seven contracts for drilling and completion services - Halliburton announced it has been awarded seven contracts for drilling and completion services for the next phase of field development of the INPEX-operated Ichthys Project in the Browse Basin offshore northern Australia. The well development campaign is due to start in March and will continue for an estimated 3-year term. The contracts awarded include directional drilling, logging while drilling, surface data logging, drilling and completions fluids, cementing, liner hangers, coring and well completions services. Halliburton's Western Australian facilities in Jandakot and Broome will support the project. The company expects to hire locally at its Broome facility to support the contract.

06:52 EST Pentair announces resignation of CFO Mark Borin - Pentair announced that Mark Borin has informed the company of his intention to resign as Executive Vice President, CFO and Chief Accounting Officer and that he has accepted an operational leadership opportunity at a private, employee-owned company. Pentair has commenced a search for the company's next CFO, and Borin plans to remain in his role with Pentair through the search process and to assist with an orderly transition.

06:49 EST Pfizer sees FY20 adjusted R&D expenses $8.1B-$8.5B - Sees FY20 effective tax rate on adjusted income approximately 15%.

06:47 EST Graphic Packaging announces settlement of $900M in U.S. pension plan obligations - Graphic Packaging is announcing the settlement of approximately $900M in pension obligations related to its largest U.S. pension plan. The benefit obligations will be settled through a combination of lump sum payments made in the fourth quarter of 2019 to plan participants electing such payments and the purchase of a group annuity contract to transfer the remaining pension benefit obligations to an annuity provider in the first quarter of 2020. The company took a non-cash settlement charge of $39.2M in the fourth quarter of 2019 related to the lump sum payments. The company anticipates taking a non-cash settlement charge of approximately $150M in the first quarter of 2020 related to the transfer of the liability to the annuity provider.

06:42 EST BorgWarner board approves $1B share repurchase program - BorgWarner also announced that its board has authorized a share repurchase program of up to $1B to be executed over the next three years. The timing and amount of any share repurchases will be based on market conditions, share price and other factors.

06:40 EST BorgWarner to acquire Delphi Technologies in all-stock deal for $3.3B

06:37 EST 3M announces new global operating model, streamlined organizational structure - Transformation,along with Portfolio, Innovation and People & Culture, is one of 3M's strategic priorities to drive long-term growth and value creation. 3M has taken several actions on its transformation journey to streamline and improve its operations, including the implementation of a new enterprise resource planning system and the April 2019 move from five to four business groups. Enabled by the success of these initiatives, 3M is announcing a new global operating model, implemented on January 1, 2020, which further aligns its four business groups - Safety & Industrial, Transportation & Electronics, Health Care, and Consumer - with the company's customers and go-to-market models. In the new model, 3M's business groups now have full responsibility for all facets of strategy, portfolio optimization and resource prioritization across their entire global operations. Under the prior model, area and country teams - which comprised 3M's International Operations organization - were responsible for setting priorities in their regions. All of 3M's international employees now report into the business groups and functions they are part of, and 3M no longer has an International Operations organization. "3M continues to transform how it operates and build a more customer-driven and streamlined organization for the future," said Mike Roman, 3M chairman and CEO. "The latest phase of our transformation journey is designed to improve growth and operational efficiency, and will enable us to create even more value for our customers and shareholders. This is a defining moment in how we run our company, and positions 3M for success in the years ahead."

06:35 EST UTC says EPS, revenue guidance for Raytheon provided after merger closes - United Technologies provided the following, regarding FY20 guidance: "Given the upcoming portfolio actions, the outlook for sales, adjusted EPS and free cash flow for Raytheon Technologies will be provided after the merger closes. The outlooks for Carrier and Otis will be provided in conjunction with their upcoming pre-spin investor meetings scheduled for February 10th and 11th, respectively."

06:32 EST 3M initiates restructuring, will cut approximately 1,500 positions - 3M announced the next step in its transformation journey, which includes a new global operating model and streamlined organizational structure. As a result of these actions, 3M initiated a restructuring that will reduce approximately 1,500 positions, spanning all business groups, functions and geographies. On a pre-tax basis, 3M took a restructuring charge of $134M in the fourth quarter of 2019. The company expects annual pre-tax savings of $110M-$120M, with $40M-$50M in 2020.

06:08 EST Mattel announces new products derived from bio-based plastic line - Mattel announced that MEGA, the Company's popular construction brand, is launching new products derived from bio-based plastic line. The number one selling pre-school construction product, Mega Bloks, will now feature three preschool building sets - Polar Friends, Safari Friends and Woodland Friends - derived from bio-based resins. The building sets have Forest Stewardship Council, or FSC,-certified packaging that is fully recyclable. The MEGA announcement is the second product that Mattel has introduced as part of its recently announced goal to achieve 100% recycled, recyclable or bio-based plastics materials in both its products and packaging by 2030.

06:06 EST Piedmont Lithium finds significant mineralization in 17 of the 19 drilled holes - Piedmont Lithium announced drill results for the final 19 drill holes of the Phase 4 drill campaign completed on the Piedmont Lithium Project located within the world-class Carolina Tin-Spodumene Bell, or TSB, in North Carolina, USA. The drill results are from the Central and Core properties. Significant mineralization was encountered in 17 of the 19 holes reported. The Phase 4 program comprised a total of 113 drill holes for 18,393 meters on both the Core and Central properties. 12 holes for 1,834 meters have been completed on the Central property since an initial Mineral Resource estimate, or MRE, was announced in April 2019. 7 holes totaling 820 meters have been completed at Core property since announcing an updated MRE in June 2019. At both properties, the drilling was predominantly focused on Exploration Target areas. These drill results continue to expand the extent of mineralization on both properties. At Central, mineralization has been extended laterally, to the southwest, and down dip. At the Core property, 5 of the 7 holes confirmed a significant new flat lying pegmatite in the southwest portion of the property.

06:03 EST Polaris Industries CEO says ended 2019 with 'positive retail momentum' - Scott Wine, Chairman and CEO of Polaris said, "We ended the year with positive fourth quarter retail momentum in both Off-Road Vehicles and Motorcycles, supporting strong full year, broad-based sales growth of 12 percent. While TAP grew modestly in the fourth quarter, non-TAP Parts, Garments and Accessories (PG&A) and aftermarket sales stole the show, eclipsing $1 billion for the first time in 2019. Our recent leadership changes were made to spur both tactical and strategic growth, and the 37 percent increase in Indian Motorcycle sales in the fourth quarter, driven largely by the Indian Challenger, demonstrates what is possible as Mike Dougherty takes over that important segment. Steve Menneto is aggressively moving to accelerate retail performance in Off-Road Vehicles and Snowmobiles, building off a strong year of financial performance in our largest business. In 2019, we delivered strong operational performance across Polaris, especially productivity and delivery, and we expect further gains to create value for customers and shareholders in the year ahead. Our commitment to being a customer-centric highly profitable growth company is unwavering, and I am extremely confident in this Polaris team to deliver on that promise."

05:59 EST Airbus reaches preliminary agreement to end global corruption probe - Airbus confirms that it has reached agreement in principle with the French Parquet National Financier, the U.K. Serious Fraud Office and the U.S. authorities. These agreements are made in the context of investigations into allegations of bribery and corruption as well as compliance with the U.S. International Traffic in Arms Regulations, Airbus said in a statement. They remain subject to approval by French and U.K. courts and U.S. court and regulator, it added. For legal reasons, Airbus said it cannot make any comments on the details of its discussions with the investigating authorities. Reference Link

05:10 EST Genpact forms strategic alliance with Amplexor - Amplexor and Genpact announced that they are forming a strategic alliance where Genpact will provide enhanced Digital Transformation services to support Amplexor's Regulatory Information Management, or RIM, solution. As part of this partnership, Genpact is creating an integrated, end-to-end Regulatory-as-a-Service, or RaaS, offering, leveraging Amplexor's RIM solution. The new service will blend Genpact's strengths in regulatory product lifecycle management with Amplexor's unified and holistic RIM solution, enabling life sciences companies to take advantage of an unrivalled, end-to-end proposition with full business process support.